NAPA Advisory Council 2021 Meeting Material

This page provides the material available for the Advisory Council meetings held in 2021.

October 25, 2021 — Advisory Council

During this meeting, the Advisory Council heard presentations about ways to support and strengthen the long-term services and supports direct care workforce, both paid and unpaid, to support access to care, improve the quality of caregiving, and meet the growing demand for long-term care dementia services. The Advisory Council also heard about a recent workshop on the behavioral and social research and clinical practice implications of preclinical diagnosis of AD/ADRD, as well as the AD/ADRD decadal study conducted by the National Academies of Sciences, Engineering, and Medicine. Federal representatives provided updates on work towards the goals of the National Plan to Address Alzheimer’s Disease in the last quarter. Material available from this meeting are listed below:

General Material:

• Document

  Meeting Announcement (pdf)
• Document

  Agenda (pdf)
• Document

  Meeting Summary (pdf)
• Public Comments

Presentation Slides:

• Document

  Voices From the Field 1 (pdf)
• Document

  Health Care and Health Support Workforce Outlook (pdf)
• Document

  Building Quality Dementia Care Through Quality Direct Care Jobs (pdf)
• Document

  The Future of LTSS Policy (pdf)
• Document

  The State of Caregiving in Wisconsin (pdf)
• Document

  Voices from the Field 2 (pdf)
• Document

  Behavioral and Social Science Research and Clinical Practice Implications of Preclinical Diagnosis of AD/ADRD (pdf)
• Document

  Reducing the Impact of Dementia in America (pdf)
• Document

  Federal Updates (pdf)

Videos:

• Part 1: “Welcome” to “Building Quality Dementia Care…”
• Part 2: “Future of LTSS Policy” to “Closing Remarks and Adjourn”

---

July 19, 2021

During the meeting, the Advisory Council discussed the implications of and opportunities presented by the approval of aducanumab. The Council heard updates from federal workgroups on efforts undertaken in the last quarter. The risk reduction subcommittee presented a summary of their work and recommendations. The research, clinical care, and long-term services and supports subcommittees also presented recommendations and the non-federal Council members voted on adopting them. Material available from this meeting is listed below:

General Material:

• Document

  Meeting Announcement (pdf)
• Document

  Agenda (pdf)
• Document

  Meeting Summary (pdf)
• Public Comments

Handouts

• Document

  Proposed Recommendations from the Public Members of NAPA Subcommittees (pdf)
• Document

  Risk Reduction Subcommittee 2021 Proposed Recommendations (pdf)

Presentation Slides:

• Document

  Impact of New/Emerging Changes in Standard Cancer Treatments on Clinical Trial Enrollment (pdf)
• Document

  Aducanumab: Considerations for Scientific Workforce Diversity (pdf)
• Document

  Federal Agency Updates (pdf)
• Document

  FY 2023 Bypass Budget (pdf)
• Document

  Risk Reduction Recommendations (pdf)
• Document

  Committee Recommendations (pdf)

Videos:

• Part 1, Welcome through Implications and Opportunities from Aducanumab Approval
• Part 2, Federal Agency Updates through Risk Reduction Recommendations
• Part 3, Subcommittee Recommendations through Conclusion

---

May 3, 2021 - Advisory Council Meeting

During the meeting the Advisory Council will hear invited presentations from a panel of experts on dementia detection and diagnosis, care models, and access to care for those with younger onset dementia. Federal workgroups will also provide updates on work completed in the last quarter. Material available from this meeting is listed below:

General Material:

• Meeting Announcement
• Agenda
• Meeting Summary
• Public Comments

Presentation Slides:

• Medicare and the 24 Month Gap in Coverage
• Panel II: Improving Timely Diagnosis of Dementia in Diverse Communities
• Wisconsin's Early Detection Engine
• Improving Timely Diagnosis of Dementia in Diverse Communities: Barriers and Facilitators in Primary Care
• Approaches to Improving Dementia Diagnosis in Diverse Communities
• Advancing Value-Based Reimbursement for Dementia Care
• Working Toward Value Based Primary Care for Dementia
• Disseminating and Implementing Successful Dementia Care Programs
• Federal Agency Updates

Videos:

• Part 1, Welcome through Panel I
• Part 2, Panel II through Summary and Next Steps
• Part 3, Federal Updates through Conclusion

---

January 25, 2021 - Advisory Council Meeting

This meeting was held virtually. At this meeting the Advisory Council heard presentations on the impact of COVID-19 on people with dementia, health disparities in dementia research, and the implications of new technologies to identify Alzheimer’s disease through a blood test. Material available from this meeting is listed below:

General Material:

• Meeting Announcement
• Agenda
• Meeting Summary
• Public Comments

Handouts:

• Federal Updates

Presentation Slides: 

• Impact of COVID on Medicare Fee-for-Service Beneficiaries with Dementia
• COVID-19 Vaccine Implementation
• Research Update on Racial and Ethnic Disparities in Dementia
• An Update on NIA’s Clinical Research Recruitment & Retention Initiatives
• Nomenclature
• Update on blood based biomarkers for Alzheimer’s Disease
• Risk Reduction Goal: Updates

Videos:

• Part 1, Welcome through "Racial and Ethnic Disparities in Dementia Research"
• Part 2, "An Update on NIA's Clinical Research Recruitment and Retention Initiatives" through Conclusion

Comments and questions, or alerts to broken links, should be sent to napa@hhs.gov.